Biogen (BIIB) Stock Forecast & Price Target

Compare

4,844 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BIIB Analyst Ratings

Moderate Buy

12 Buy

14 Hold

0 Sell

Based on 26 analysts giving stock ratings to

Biogen

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BIIB Stock 12 Month Forecast

Average Price Target

$166.60

▲(29.46%Upside)

Based on 26 Wall Street analysts offering 12 month price targets for Biogen in the last 3 months. The average price target is $166.60 with a high forecast of $255.00 and a low forecast of $115.00. The average price target represents a 29.46% change from the last price of $128.69.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"114":"$114","185":"$185","256":"$256","149.5":"$149.5","220.5":"$220.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":255,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$255.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":166.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$166.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":115,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$115.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[114,149.5,185,220.5,256],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,130.07,139.68,149.29,158.9,168.51,178.12,187.73000000000002,197.34,206.95,216.56,226.17000000000002,235.78,245.39000000000001,{"y":255,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,130.07,132.88,135.69,138.5,141.31,144.12,146.93,149.74,152.54999999999998,155.35999999999999,158.17,160.98,163.79,{"y":166.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,130.07,128.91076923076923,127.75153846153846,126.59230769230768,125.43307692307692,124.27384615384615,123.11461538461538,121.95538461538462,120.79615384615384,119.63692307692307,118.47769230769231,117.31846153846153,116.15923076923077,{"y":115,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":231.77,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":210.7,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":204.76,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":190.8,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":173.79,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":164.23,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":152.92,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":143.93,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":140.5,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":132.03,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":120.93,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":131.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 41, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.07,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$255.00

Average Price Target$166.60

Lowest Price Target$115.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$140

Buy

8.79%

Upside

Reiterated

07/16/25

Biogen's overall stock score is driven primarily by its financial stability and strategic focus on new product growth, despite declining revenue in its traditional segments. The technical analysis suggests potential short-term weakness, while valuation metrics indicate fair pricing. The positive sentiment from the earnings call supports a balanced outlook with both opportunities and challenges.

Laura ChicoWedbush

Wedbush

$121→$129

Hold

0.24%

Upside

Reiterated

07/17/25

Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (NASDAQ: SRPT) and Biogen (NASDAQ: BIIB)

Mohit BansalWells Fargo

Wells Fargo

$140

Hold

8.79%

Upside

Reiterated

07/14/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Ascendis Pharma (NASDAQ: ASND) and Biogen (NASDAQ: BIIB)

Ashwani VermaUBS

UBS

$119→$130

Hold

1.02%

Upside

Reiterated

07/14/25

UBS Remains a Hold on Biogen (BIIB)

Chris SchottJ.P. Morgan

J.P. Morgan

$175

Hold

35.99%

Upside

Reiterated

07/11/25

Biogen's Hold Rating: Navigating Current Challenges and Future Opportunities

Terence FlynnMorgan Stanley

Morgan Stanley

$146

Hold

13.45%

Upside

Reiterated

07/10/25

Biogen (BIIB) Gets a Hold from Morgan Stanley

Brian AbrahamsRBC Capital

RBC Capital

$208

Buy

61.63%

Upside

Reiterated

07/10/25

Biogen (BIIB) Gets a Buy from RBC Capital

Evan SeigermanBMO Capital

BMO Capital

$128

Hold

-0.54%

Downside

Reiterated

07/09/25

Biogen (BIIB) Gets a Hold from BMO Capital

David AmsellemPiper Sandler

Piper Sandler

$115

Hold

-10.64%

Downside

Reiterated

07/08/25

Piper Sandler Sticks to Its Hold Rating for Biogen (BIIB)

George FarmerScotiabank

Scotiabank

$224

Buy

74.06%

Upside

Reiterated

07/08/25

Scotiabank Reaffirms Their Buy Rating on Biogen (BIIB)

Andrew FeinH.C. Wainwright

H.C. Wainwright

$187

Buy

45.31%

Upside

Reiterated

06/26/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

William PickeringBernstein

Bernstein

―

Hold

―

Reiterated

06/19/25

Biogen (BIIB) Receives a Hold from Bernstein

Sumant KulkarniCanaccord Genuity

Canaccord Genuity

$220

Buy

70.95%

Upside

Reiterated

06/16/25

Biogen's Strategic Diversification and Promising Pipeline Drive Buy Rating

Ami FadiaNeedham

Needham

―

Hold

―

Reiterated

06/12/25

Biogen's Hold Rating: Navigating Opportunities and Challenges in Clinical Developments

Srikripa DevarakondaTruist Financial

Truist Financial

―

Buy

―

Reiterated

06/12/25

Truist Financial Remains a Buy on Biogen (BIIB)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$140

Buy

8.79%

Upside

Reiterated

07/16/25

Laura ChicoWedbush

Wedbush

$121→$129

Hold

0.24%

Upside

Reiterated

07/17/25

Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (NASDAQ: SRPT) and Biogen (NASDAQ: BIIB)

Mohit BansalWells Fargo

Wells Fargo

$140

Hold

8.79%

Upside

Reiterated

07/14/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Ascendis Pharma (NASDAQ: ASND) and Biogen (NASDAQ: BIIB)

Ashwani VermaUBS

UBS

$119→$130

Hold

1.02%

Upside

Reiterated

07/14/25

UBS Remains a Hold on Biogen (BIIB)

Chris SchottJ.P. Morgan

J.P. Morgan

$175

Hold

35.99%

Upside

Reiterated

07/11/25

Biogen's Hold Rating: Navigating Current Challenges and Future Opportunities

Terence FlynnMorgan Stanley

Morgan Stanley

$146

Hold

13.45%

Upside

Reiterated

07/10/25

Biogen (BIIB) Gets a Hold from Morgan Stanley

Brian AbrahamsRBC Capital

RBC Capital

$208

Buy

61.63%

Upside

Reiterated

07/10/25

Biogen (BIIB) Gets a Buy from RBC Capital

Evan SeigermanBMO Capital

BMO Capital

$128

Hold

-0.54%

Downside

Reiterated

07/09/25

Biogen (BIIB) Gets a Hold from BMO Capital

David AmsellemPiper Sandler

Piper Sandler

$115

Hold

-10.64%

Downside

Reiterated

07/08/25

Piper Sandler Sticks to Its Hold Rating for Biogen (BIIB)

George FarmerScotiabank

Scotiabank

$224

Buy

74.06%

Upside

Reiterated

07/08/25

Scotiabank Reaffirms Their Buy Rating on Biogen (BIIB)

Andrew FeinH.C. Wainwright

H.C. Wainwright

$187

Buy

45.31%

Upside

Reiterated

06/26/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

William PickeringBernstein

Bernstein

―

Hold

―

Reiterated

06/19/25

Biogen (BIIB) Receives a Hold from Bernstein

Sumant KulkarniCanaccord Genuity

Canaccord Genuity

$220

Buy

70.95%

Upside

Reiterated

06/16/25

Biogen's Strategic Diversification and Promising Pipeline Drive Buy Rating

Ami FadiaNeedham

Needham

―

Hold

―

Reiterated

06/12/25

Biogen's Hold Rating: Navigating Opportunities and Challenges in Clinical Developments

Srikripa DevarakondaTruist Financial

Truist Financial

―

Buy

―

Reiterated

06/12/25

Truist Financial Remains a Buy on Biogen (BIIB)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Biogen

1 Month

xxx

Success Rate

16/33 ratings generated profit

Average Return

+0.69%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 48.48% of your transactions generating a profit, with an average return of +0.69% per trade.

3 Months

xxx

Success Rate

15/33 ratings generated profit

Average Return

-1.43%

reiterated a xxx

rating 9 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 45.45% of your transactions generating a profit, with an average return of -1.43% per trade.

1 Year

Marc GoodmanLeerink Partners

Success Rate

9/34 ratings generated profit

Average Return

-11.49%

reiterated a buy rating last month

Copying Marc Goodman's trades and holding each position for 1 Year would result in 26.47% of your transactions generating a profit, with an average return of -11.49% per trade.

2 Years

xxx

Success Rate

10/39 ratings generated profit

Average Return

-20.96%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 25.64% of your transactions generating a profit, with an average return of -20.96% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BIIB Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BIIB has received 28 Buy Ratings, 32 Hold Ratings, and 0 Sell Ratings. BIIB average Analyst price target in the past 3 months is 166.60.

Each month's total comprises the sum of three months' worth of ratings.

BIIB Financial Forecast

BIIB Earnings Forecast

Next quarter’s earnings estimate for BIIB is $3.99 with a range of $3.60 to $4.80. The previous quarter’s EPS was $3.02. BIIB beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.16% of the time in the same period. In the last calendar year BIIB has Preformed in-line its overall industry.

BIIB Sales Forecast

Next quarter’s sales forecast for BIIB is $2.32B with a range of $2.24B to $2.40B. The previous quarter’s sales results were $2.34B. BIIB beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.45% of the time in the same period. In the last calendar year BIIB has Preformed in-line its overall industry.

BIIB Stock Forecast FAQ

What is BIIB’s average 12-month price target, according to analysts?

Based on analyst ratings, Biogen’s 12-month average price target is 166.60.

What is BIIB’s upside potential, based on the analysts’ average price target?

Biogen has 29.46% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BIIB a Buy, Sell or Hold?

Biogen has a consensus rating of Moderate Buy which is based on 12 buy ratings, 14 hold ratings and 0 sell ratings.

What is Biogen’s price target?

The average price target for Biogen is 166.60. This is based on 26 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $255.00 ,the lowest forecast is $115.00. The average price target represents 29.46% Increase from the current price of $128.69.

What do analysts say about Biogen?

Biogen’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 26 Wall Streets Analysts.

How can I buy shares of BIIB?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Biogen (BIIB) Stock Forecast & Price Target

BIIB Analyst Ratings

BIIB Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Biogen

BIIB Analyst Recommendation Trends

BIIB Financial Forecast

BIIB Earnings Forecast

BIIB Sales Forecast

BIIB Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts